* A directed share issue adds MSEK 4.2 before costs * First patient enrolment expected as next trigger * We keep our fair value of SEK 0.06 per share
ANNONS
Gabather has carried out a directed share issue of approximately MSEK 4.2 with participation from several investors, improving the company’s cash position. Together with earlier warrant exercises and improved cost control, this reduces financial risk and extends the funding runway. Further progress updates on the phase II clinical trial of GT-002 in Denmark are awaited.
